



## Europass Curriculum Vitae

### Personal information

First name(s) / Surname(s) **Cosimo Durante**  
Address(es) Department of Translational and Precision Medicine, University of Rome Sapienza  
Viale del Policlinico 155, 00161 – Rome, Italy  
E-mail cosimo.durante@uniroma1.it

**Occupational field** Medical Doctor/Full Professor of Internal Medicine

### Present title and affiliation

Date	01/11/2023 →
Occupation or position held	President of the single-cycle degree course in Medicine and Surgery “A”
Name and address of employer	University of Rome Sapienza – Faculty of Pharmacy and Medicine
Dates	31/03/2022 →
Occupation or position held	Full Professor of Internal Medicine
Main activities and responsibilities	Research, teaching (research and clinical training), mentorship, clinical care
Name and address of employer	Department of Translational and Precision Medicine, University of Rome Sapienza Viale del Policlinico 155, 00161 – Rome, Italy
Sector	Internal Medicine
Dates	14/12/2016 →
Occupation or position held	Chief of the “Unit on the Management of Advanced Thyroid Cancer Patients”
Main activities and responsibilities	Diagnosis and treatment of patients with thyroid tumors, advanced thyroid cancers
Name and address of employer	Policlinico Umberto I Hospital. Department of Translational and Precision Medicine, University of Rome Sapienza Viale del Policlinico 155, 00161 – Rome, Italy
Sector	Internal Medicine. Endocrine Oncology.

### Education and training

Dates	1994 - 2000
Title of qualification awarded	Degree in Medicine and Surgery
Name and type of organisation providing education and training	University of Rome Sapienza
Dates	2000 - 2005
Title of qualification awarded	Board in Endocrinology and Metabolism
Name and type of organisation providing education and training	University of Rome Sapienza
Dates	2005 - 2008
Title of qualification awarded	PhD degree in Endocrinology and Molecular Medicine
Name and type of organisation providing education and training	University of Rome Sapienza

## Fellowships

Dates 2003 - 2004  
Name and type of organisation providing the fellowship Clinical and Research Fellowship at the Nuclear Medicine and Endocrine Tumor Department, Cancer Institut "Gustave Roussy", Villejuif, France – Martin Schlumberger, MD

## Work experience

### Academic Appointments

Dates 01/11/2008 – 17/01/2019  
Occupation or position held Assistant Professor of Internal Medicine  
Main activities and responsibilities Research, teaching (research and clinical training), mentorship, clinical care  
Name and address of employer Department of Internal Medicine and Medical Specialties, University of Rome Sapienza Viale del Policlinico 155, 00161 – Rome, Italy  
Sector Internal Medicine

Dates 18/01/2019 – 30/03/2022  
Occupation or position held Associate Professor of Internal Medicine  
Main activities and responsibilities Research, teaching (research and clinical training), mentorship, clinical care  
Name and address of employer Department of Translational and Precision Medicine, University of Rome Sapienza Viale del Policlinico 155, 00161 – Rome, Italy  
Sector Internal Medicine

Dates 31/03/2022 →  
Occupation or position held Full Professor of Internal Medicine  
Main activities and responsibilities Research, teaching (research and clinical training), mentorship, clinical care  
Name and address of employer Department of Translational and Precision Medicine, University of Rome Sapienza Viale del Policlinico 155, 00161 – Rome, Italy  
Sector Internal Medicine

### Institutional Committee Activities

Dates 2014-2015  
Institution Italian Society of Endocrinology (SIE)  
Activity Member of the SIE Task Force for the preparation of the document: "Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology"

Dates 2015-2020  
Institution Italian Association Of Medical Oncology (AIOM)  
Activity Scientific secretary of the Italian Association Of Medical Oncology (AIOM) Task Force for the preparation of the document: "AIOM Thyroid Tumors Guidelines". Editions 2016, 2017, 2018, 2019

Dates 2016-2017  
Institution European Thyroid Association (ETA)  
Activity Member of the ETA Task Force for the preparation of the document: "European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS", Edition 2017

Dates 2016-2018

Institution	Italian Thyroid Association (AIT), Medical Endocrinology Association (AME), Italian Society of Endocrinology (SIE), Italian Association of Nuclear Medicine and Molecular Imaging (AIMN), Italian Society of Unified Endocrine Surgery (SIUEC), Italian Society of Anatomic Pathology and Diagnostic Cytology (SIAPEC)
Activity	Member of the AIT, AME, SIE, AIMN, SIUEC, SIAPEC Task Force for the preparation of the document: "Italian Consensus on Diagnosis and Treatment of Differentiated Thyroid Cancer: Joint Statements of Six Italian Societies"
Dates	2017-2018
Institution	Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB), Italian Society of Medical Radiology (SIRM)
Activity	Member of the AIT, SIE, SIUMB, SIRM Task Force for the preparation of the document: "Thyroid ultrasonography reporting: consensus of Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB) and Ultrasound Chapter of Italian Society of Medical Radiology (SIRM)"
Dates	2017-Present
Institution	European Society for Medical Oncology (ESMO)
Activity	Member of the ESMO Task Force for the preparation of the document: "ESMO Clinical Practice Guidelines on Thyroid Cancer"
Dates	2018-Present
Institution	International Thyroid Oncology Group (ITOG)
Activity	Member of the ITOG Task Force for establishing an International Advanced Thyroid Cancer Registry
Dates	2018-Present
Institution	American Association of Clinical Endocrinologists (AACE), American College of Radiology (ACR), American Thyroid Association (ATA), European Thyroid Association (ETA), Korean Society of Thyroid Radiology (KSThR), Korean Society of Ultrasound in Medicine (KSUM)
Activity	Member of the International Thyroid Nodule Work Group (ITNWG) Task Force for establishing an Universal Thyroid Imaging Reporting And Data System (TIRADS)
Dates	2019-Present
Institution	American Thyroid Association (ATA)
Activity	Member of the American Thyroid Association (ATA) Thyroid Nodules Task Force for the preparation of the document: "American Thyroid Association guidelines on the management of thyroid nodules"
Dates	2020-Present
Institution	Italian Association of Medical Oncology (AIOM)
Activity	Member of the Italian Association of Medical Oncology (AIOM) Task Force for the preparation of the document: "AIOM Thyroid Tumors Guidelines"
Dates	2021-Present
Institution	European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB)
Activity	Member of the EFSUMB Task Force for the preparation of the document: "EFSUMB Thyroid Multiparametric Ultrasound Guidelines"
Dates	2022-Present
Institution	European Thyroid Association (ETA)

Activity	Chair of the ETA Task Force for the preparation of the document: "European Thyroid Association Guidelines for Thyroid Nodule management"
<b>Editor/Service on Editorial Board(s)</b>	
Dates	01/01/2014 – 31/12/2016
Journal	"The Journal of Endocrinological Investigation" (InCites Journal Impact Factor Quartile: Q2)
Activity	Editorial Board Member
Dates	01/01/2014 – 31/12/2017
Journal	"The Journal of Clinical Endocrinology & Metabolism" (InCites Journal Impact Factor Quartile: Q1)
Activity	Editorial Board Member
Dates	01/10/2018 – 31/12/2021
Journal	"Endocrine" (InCites Journal Impact Factor Quartile: Q2)
Activity	Associate Editor
Dates	01/01/2019 – 31/12/2021
Journal	"Thyroid" (InCites Journal Impact Factor Quartile: Q1)
Activity	Editorial Board Member
Dates	01/01/2020 – 31/12/2021
Journal	The Journal of Clinical Endocrinology & Metabolism" (InCites Journal Impact Factor Quartile: Q1)
Activity	Editorial Board Member
Dates	01/01/2022 →
Journal	"Thyroid" (InCites Journal Impact Factor Quartile: Q1)
Activity	Associate Editor
Dates	01/01/2022 →
Journal	"Endocrine" (InCites Journal Impact Factor Quartile: Q2)
Activity	Editorial Board Member
<b>Clinical trials experience</b>	
Dates	2004-2005
Position	Sub-Investigator
Research study title	A Phase 2, Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer who are not Candidate for Radioactive Iodine Therapy (ClinicalTrials.gov: NCT00121628)
Dates	2006-2016
Position	Sub-Investigator (2006-2015) – Principal Investigator (from September 1 <sup>st</sup> , 2015)
Research study title	An International, Phase II/III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (Zactima) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT0041076. Study ID Number: D4200C00058)
Dates	2009-2014

Position	Sub-Investigator
Research study title	A Phase II, Multicenter, Open Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (ClinicalTrials.gov: NCT00784303. Study ID Number: E7080-G000-201)
Dates	2009-2014
Position	Sub-Investigator
Research study title	An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT00704730. Study ID Number: XL184-301)
Dates	2010-2018
Position	Sub-Investigator (2010-2015) – Principal Investigator (from September 1 <sup>st</sup> , 2015)
Research study title	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01321554. Study ID Number: E7080-G000-303)
Dates	2011-2014
Position	Sub-Investigator
Research study title	A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib (ClinicalTrials.gov: NCT01298323. Study ID Number: D4200C00088)
Dates	2012-2015
Position	Sub-Investigator
Research study title	An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease (ClinicalTrials.gov: NCT01496313. Study ID Number: D4200C00097)
Dates	2013-2017
Position	Sub-Investigator (2013-2015) – Principal Investigator (from September 1 <sup>st</sup> , 2015)
Research study title	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy (ClinicalTrials.gov: NCT01876784. Study ID Number: D4203C00011)
Dates	2013-2018
Position	Sub-Investigator (2013-2015) – Principal Investigator (from September 1 <sup>st</sup> , 2015)
Research study title	A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01843062. Study ID Number: D1532C00065)
Dates	2017-2021
Position	Principal Investigator
Research study title	A Randomized, Double-Blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients (ClinicalTrials.gov: NCT01896479. Study ID Number: XL184-401)
Dates	2019-2020
Position	Sub-Investigator

Research study title	A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (ClinicalTrials.gov: NCT03037385. Study ID Number: BLU-667-1101)
Dates	2019 →
Position	Principal Investigator
Research study title	A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR Targeted Therapy (ClinicalTrials.gov: NCT03690388. Study ID Number: XL184-311)
Date	2020 →
Posizione	Principal-Investigator
Titolo della sperimentazione	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (ClinicalTrials.gov: NCT04211337. Study ID Number: J2G-MC-JZJB)

**Please note: all these clinical trials included a GCP training**

### Honors and Awards

Date	2019
Award	The 2019 “Gaetano Salvatore” International Prize in Thyroid Physiopathology
Name and type of organisation providing the award	Accademia Nazionale dei Lincei

### Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment  
European level (\*)

**English**

**French**

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C2	Proficient user	C2	Proficient user	C1	Proficient user	C1	Proficient user	C2	Proficient user
C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user

(\*) [Common European Framework of Reference for Languages](#)

### Publications

Articles	186
Impact factor (last)	1639 (InCites Journal Impact Factor)
Sum of the times cited	10715 (Scopus)
H-index	47 (Scopus)

### Annexes

Articles in international peer-reviewed journals, indexed in PubMed

- Corneli G, Baldelli R, Di Somma C, Grottoli S, **Durante C**, Gasco V, Ferretti E, Colao A, Tamburrano G, Lombardi G, Aimaretti G, Ghigo E. Evaluation of GH deficiency by GHRH + arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. **J Endocrinol Invest.** 2002;25(10 Suppl):38-9.
- Tamburrano G, **Durante C**, Baldelli R. Therapy of diabetes and dyslipidemia in acromegaly. **Pituitary.** 2002;5(1):27-31.
- Corneli G, Baldelli R, Di Somma C, Rovere S, Gaia D, Pellegrino M, Gasco V, **Durante C**,

- Grottoli S, Colao A, Tamburrano G, Lombardi G, Ghigo E, Aimaretti G. Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. *Growth Horm IGF Res.* 2003;13(2-3):104-108.
4. Aimaretti G, Corneli G, Baldelli R, Di Somma C, Gasco V, **Durante C**, Ausiello L, Rovere S, Grottoli S, Tamburrano G, Ghigo E. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. *Clin Endocrinol (Oxf).* 2003;59(1):56-61.
  5. Baldelli R, **Durante C**, D'Amico E, Diacono F, Tamburrano G, Casanueva FF. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. *J Endocrinol Invest.* 2003;26(12):1219-24.
  6. **Durante C**, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab.* 2006;91(8):2892-9.
  7. **Filetti S**, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. *Nat Clin Pract Endocrinol Metab.* 2006;2(7):384-94.
  8. Costante G, Meringolo D, **Durante C**, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab.* 2007;92(2):450-455.
  9. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, **Durante C**, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. *Thyroid.* 2007;17(4):363-6.
  10. **Durante C**, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab.* 2007;92(7):2840-3.
  11. Montesano T\*, **Durante C\***, Attard M, Crocetti U, Meringolo D, Bruno R, Tumino S, Ribello D, Al-Nahhas A, Colandrea M, Maranghi M, Tralascio L, Ronga G, Torlontano M. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. *Biomed Pharmacother.* 2007;61(8):468-71. \***Equal contribution**
  12. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, Meringolo D, Arturi F, **Durante C**, Amorosi A, Foschini MP, Nardi F, Russo D, Filetti S. hNIS protein in thyroid: the iodine supply influences its expression and localization. *Thyroid.* 2007;17(7):613-8.
  13. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, **Durante C**, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivatives. *J Endocrinol Invest.* 2007;30(10):RC31-4.
  14. Torlontano M\*, **Durante C\***, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (thr92ala) predicts l-thyroxine dose to achieve target TSH levels in thyroidectomized patients. *J Clin Endocrinol Metab.* 2008;93(3):910-913. \***Equal contribution**
  15. Puxeddu E, **Durante C**, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. *Trends Endocrinol Metab.* 2008;19(4):138-145.
  16. Ferretti E, Tosi E, Po A, Scipioni A, Morisi R, Espinola MS, Russo D, **Durante C**, Schlumberger M, Screpanti I, Filetti S, Gulino A. Notch signaling is involved in expression of thyrocyte differentiation markers and is downregulated in thyroid tumors. *J Clin Endocrinol Metab.* 2008;93(19):4080-4087.
  17. Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, **Durante C**, Pacini F. Short telomeres, hTERT gene amplification and increased telomerase activity in the blood of familial non-medullary thyroid cancer patients. *J Clin Endocrinol Metab.* 2008;93(10):3950-3957.
  18. Crocetti U, **Durante C**, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients.

*Thyroid*. 2008;18(10):1049-1053.

19. Costante G, **Durante C**, Zelia Francis, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab*. 2009;5(1):35-44.
20. **Durante C**, Boukheris H, Dromain C, Duvillard P, Lebouleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. *Endocr Relat Cancer*. 2009;16(2):585-97.
21. Sponziello M, Scipioni A, **Durante C**, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D. Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines. *J Endocrinol Invest*. 2010;33(1):2-6.
22. Maranghi M, Pugliese F, Cianci R, Colotto M, **Durante C**, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, Filetti S. Atherosclerosis renal artery stenosis and in-stent restenosis in a diabetic patient: Targeting on diabetic dyslipidemia is a key intervention. *J Endocrinol Invest*. 2010;33(4):284-5.
23. Castellone MD, Verrienti A, Rao DM, Sponziello M, Fabbro D, Muthu M, **Durante C**, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: Functional characterization. *Clin Endocrinol (Oxf)*. 2010;73(4):529-534.
24. **Durante C**, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S; on behalf of the Papillary Thyroid Cancer Study Group. Identification and Optimal Postsurgical Follow-Up of Patients with Very Low-Risk Papillary Thyroid Microcarcinomas. *J Clin Endocrinol Metab*. 2010;95(11):4882-8.
25. Sponziello ML, Bruno R, **Durante C**, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res*. 2011;43(1):22-5.
26. Colotto M, Maranghi M, Epifania A, Totaro M, Giura R, **Durante C**. Unmasking aortic dissection in patients of transient global amnesia: case report and diagnostic algorithm for the emergency department. *BMJ Case Rep*. 2011 Jan 25;2011. pii: bcr0720103151. doi: 10.1136/bcr.07.2010.3151.
27. Colotto M, Maranghi M, **Durante C**, Rossetti M, Renzi A, Anatra MG. PFAPA Syndrome in a Young Adult with a History of Tonsillectomy. *Intern Med*. 2011;50(3):223-5.
28. **Durante C**, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. *Expert Opin Investig Drugs*. 2011;20(3):407-413.
29. Russo D, Damante G, Puxeddu E, **Durante C**, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. *J Mol Endocrinol*. 2011;46(3):R73-81.
30. Russo D, Scipioni A, **Durante C**, Ferretti E, Gandini L, Maggisano V, Paoli D, Verrienti A, Costante G, Lenzi A, Filetti S. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. *Endocrine*. 2011;40(1):35-40.
31. **Durante C**, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol*. 2011 Sep;165(3):455-63.
32. Mastroianno S, Torlontano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, **Durante C**, Filetti S. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. *Endocrine*. 2011 Dec;40(3):481-5.
33. **Durante C**, Filetti S. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. *J Clin Endocrinol Metab*. 2011 Oct;96(10):3059-61.
34. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G,



- Puxeddu E, Filetti S, Russo D, **Durante C**. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep*. 2011 Nov;26(5):1075-80.
35. Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, **Durante C**, Filetti S. TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. *Endocrine*. 2011 Dec;40(3):492-4.
  36. D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, **Durante C**, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. *Thyroid*. 2012 Feb;22(2):138-44
  37. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, **Durante C**, Russo D, Filetti S, Damante G. CREM inhibits promoter activity of NIS gene in thyroid cancer cells. *Thyroid*. 2012 May;22(5):487-93
  38. **Durante C**, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? *J Clin Endocrinol Metab*. 2012 Aug;97(8):2748-53
  39. Colotto M, Renzi A, **Durante C**. Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk. *BMJ Case Rep*. 2012 Jul 17;2012. pii: bcr2012006230. doi: 10.1136/bcr-2012-006230
  40. Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, **Durante C**, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine*. 2013 Feb;43(1):147-53
  41. D'Elia AV, Grimaldi F, Pizzolitto S, De Maglio G, Bregant E, Passon N, Franzoni A, Verrienti A, Tamburrano G, **Durante C**, Filetti S, Fogolari F, Russo D, Damante G. A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. *Clin Endocrinol (Oxf)*. 2013 Mar;78(3):391-7
  42. Russo D, **Durante C**, Bulotta S, Puppini C, Puxeddu E, Filetti S, Damante G. Targeting histone deacetylase in thyroid cancer. *Expert Opin Ther Targets*. 2013 Feb;17(2):179-93
  43. **Durante C**, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. *J Clin Endocrinol Metab*. 2013 Feb;98(2):636-42.
  44. **Durante C**, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for the post-operative management. *Endocr Relat Cancer*. 2013 Jun 24;20(4):R141-54.
  45. **Durante C**, Paciaroni A, Plasmati K, Trulli F, Filetti S. Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. *Endocrine*. 2013 Oct;44(2):334-42.
  46. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppini C, Russo MA, Bruno R, Filetti S, **Durante C**, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. *Endocrinology*. 2013 Sep;154(9):3043-53.
  47. D'Agostino M, Sponziello M, Puppini C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, **Durante C**, Filetti S, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. *J Mol Endocrinol*. 2014 Jan 30;52(2):121-31.
  48. Puppini C, **Durante C**, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov;47(2):528-36.
  49. **Durante C**, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Totoda M, Redler A, Ronga G, Filetti S, Monzani F. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. *Thyroid*. 2014 Jul;24(7):1139-45.

50. Sponziello M\*, **Durante C\***, Boichard A, Dima M, Puppini C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. *Mol Cell Endocrinol*. 2014 Jul 5;392(1-2):8-13. **\*Equal contribution**
51. Maranghi M, Carnovale A, **Durante C**, Tarquini G, Tiseo G, Filetti S. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. *Expert Opin Drug Metab Toxicol*. 2015 Jan;11(1):125-37.
52. Lamartina L, **Durante C**, Filetti S, Cooper DS. Low and intermediate Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature. *J Clin Endocrinol Metab*. 2015 May;100(5):1748-61.
53. **Durante C**, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S. The natural history of benign thyroid nodules. *JAMA*. 2015 Mar 3;313(9):926-35.
54. Sponziello M, Verrienti A, Rosignolo F, De Rose RF, Pecce V, Maggisano V, **Durante C**, Bulotta S, Damante G, Giacomelli L, Di Gioia CR, Filetti S, Russo D, Celano M. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. *Endocrine*. 2015 Nov;50(2):434-41.
55. Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, **Durante C**, Celano M, Russo D, Filetti S, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. *Endocrine*. 2015 Nov;50(2):453-64.
56. Rosignolo F, Maggisano V, Sponziello M, Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A, Dima M, Pecce V, **Durante C**. Reduced expression of THR $\beta$  in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression. *J Endocrinol Invest*. 2015 Dec;38(12):1283-9.
57. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, **Durante C**, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A. TERT promoter mutations in thyroid papillary microcarcinomas. *Thyroid*. 2015 Sep;25(9):1013-9.
58. Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, Lucia P, **Durante C**, Rosignolo F, Pecce V, Sponziello M, Puppini C, Costante G, Bruno R. A novel double mutation VAL648ILE and VAL804LEU of RET proto-oncogene in Multiple Endocrine Neoplasia type 2. *Endocr Pract*. 2015 Nov;21(11):1248-54.
59. Tallini G\*, de Biase D\*, **Durante C\***, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. *Mod Pathol*. 2015 Oct;28(10):1343-59. **\*Equal contribution**
60. Sponziello M, **Durante C**, Filetti S. HABP2 Mutation and Nonmedullary Thyroid Cancer. *N Engl J Med*. 2015 Nov 19;373(21):2085-6.
61. Pacini F, Brianzoni E, **Durante C**, Elisei R, Ferdeghini M, Fugazzola L, Mariotti S, Pellegriti G. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. *J Endocrinol Invest*. 2016 Mar;39(3):341-7.
62. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, **Durante C**. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. *Endocrine*. 2016 Jul;53(1):145-56.
63. Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppini C, Filetti S, **Durante C**, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G. MCM5 as a target of BET inhibitors in thyroid cancer cells. *Endocr Relat Cancer*. 2016 Apr;23(4):335-347.
64. Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, **Durante C**, Filetti S, Damante G, Russo D, Bulotta S. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Mol Cell Endocrinol*. 2016 Aug 15;431:123-32.
65. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K,

- Sponziello M, Trulli F, Verrienti A, Filetti S, **Durante C**. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2016 Aug;101(8):3036-44.
66. Cabanillas ME, McFadden DG, **Durante C**. Thyroid cancer. *Lancet*. 2016 Dec 3;388(10061):2783-2795.
  67. Rosignolo F, Sponziello M, **Durante C**, Puppini C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G. Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. *PLoS One*. 2016 Jun 1;11(6):e0156658
  68. Lamartina L, Deandreis D, **Durante C**, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. *Eur J Endocrinol*. 2016 Nov;175(5):R185-202
  69. Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, **Durante C**. RET mutation and increased angiogenesis in medullary thyroid carcinomas. *Endocr Relat Cancer*. 2016 Aug;23(8):665-76.
  70. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, **Durante C**. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine*. 2016 Nov;54(2):467-475.
  71. Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, **Durante C**, Filetti S, Verrienti A. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. *J Endocr Soc*. 2017 Jan 12;1(1):3-13. doi: 10.1210/js.2016-1032.
  72. Giannetta E, Isidori AM, **Durante C**, Di Gioia C, Longo F, Tombolini V, Bulzonetti N, Graziadio C, Pofi R, Gianfrilli D, Verrienti A, Carletti R, Filetti S, Lenzi A, Baroli A. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. *Medicine (Baltimore)*. 2017 Feb;96(6):e5621. doi: 10.1097/MD.0000000000005621.
  73. Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, **Durante C**, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, Sponziello M. MicroRNA-based molecular classification of papillary thyroid carcinoma. *Int J Oncol*. 2017 May;50(5):1767-1777. doi: 10.3892/ijo.2017.3960.
  74. Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, **Durante C**, Filetti S, Damante G, Russo D, Bulotta S. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. *Mol Cell Endocrinol*. 2017 Jun 15;448:34-40. doi: 10.1016/j.mce.2017.03.007
  75. Grani G, Lamartina L, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, **Durante C**, Cantisani V. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. *Endocrine*. 2017 Aug;57(2):256-261. doi: 10.1007/s12020-016-1148-6.
  76. Russ G, Bonnema SJ, Erdogan MF, **Durante C**, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. *Eur Thyroid J*. 2017 Sep;6:225-237. doi: 10.1159/000478927.
  77. Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, **Durante C**. Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume. *Thyroid*. 2017 Nov;27(11):1378-1384. doi: 10.1089/thy.2017.0201
  78. Lamartina L, **Durante C**, Lucisano G, Grani G, Bellantone RA, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone PP, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Mian C, Spiazzi G, Persani L, Barbaro D, Nicolucci A, Filetti S. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory. *Thyroid*. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299.
  79. Celano M, Mignogna C, Rosignolo F, Sponziello M, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, **Durante C**, Di Loreto C, Damante G, Russo D. Expression

- of YAP1 in aggressive thyroid cancer. *Endocrine*. 2018 Jan;59(1):209-212. doi: 10.1007/s12020-017-1240-6.
80. Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, **Durante C**, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. *Endocrine*. 2018 Jan;59(1):90-101. doi: 10.1007/s12020-017-1455-6.
  81. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, **Durante C**. Interobserver agreement of various thyroid imaging reporting and data systems. *Endocr Connect*. 2018 Jan;7(1):1-7. doi: 10.1530/EC-17-0336.
  82. Lamartina L, Grani G, **Durante C**, Filetti S. Recent advances in managing differentiated thyroid cancer. *F1000Res*. 2018 Jan 18;7:86. doi: 10.12688/f1000research.12811.1.
  83. Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzi AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, **Durante C**, Verrienti A. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. *Hum Mutat*. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378.
  84. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, **Durante C**. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. *Endocr Relat Cancer*. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453.
  85. **Durante C**, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. *JAMA*. 2018 Mar 6;319(9):914-924. doi: 10.1001/jama.2018.0898.
  86. Lombardo GE, Maggisano V, Celano M, Cosco D, Mignogna C, Baldan F, Lepore SM, Allegri L, Moretti S, **Durante C**, Damante G, Fresta M, Russo D, Bulotta S, Puxeddu E. Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. *Mol Cancer Ther*. 2018 Jun;17(6):1187-1195. doi: 10.1158/1535-7163.MCT-17-0559.
  87. Grani G, Lamartina L, **Durante C**, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol*. 2018 Jun;6(6):500-514. doi:10.1016/S2213-8587(17)30325-X.
  88. Falcone R, Ramundo V, Lamartina L, Ascoli V, Bosco D, Di Gioia C, Montesano T, Biffoni M, Bononi M, Giacomelli L, Minni A, Segni M, Maranghi M, Cantisani V, **Durante C**, Grani G. Sonographic Presentation of Metastases to the Thyroid Gland: A Case Series. *J Endocr Soc*. 2018 Jun 21;2(8):855-859. doi:10.1210/js.2018-00124.
  89. Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, **Durante C**, Elisei R, Fadda G, Frasoldati A, Fugazzola L, Guglielmi R, Lombardi CP, Miccoli P, Papini E, Pellegriti G, Pezzullo L, Pontecorvi A, Salvatori M, Seregini E, Vitti P. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. *J Endocrinol Invest*. 2018 Jul;41(7):849-876. doi: 10.1007/s40618-018-0884-2.
  90. Celano M, Mio C, Sponziello M, Verrienti A, Bulotta S, **Durante C**, Damante G, Russo D. Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. *Mol Cell Endocrinol*. 2018 Jul 5;469:38-47. doi: 10.1016/j.mce.2017.05.036.
  91. Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, **Durante C**. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy. *Thyroid*. 2018 Sep;28(9):1190-1197. doi: 10.1089/thy.2018.0178
  92. Lamartina L, Grani G, **Durante C**, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. *Nat Rev Endocrinol*. 2018 Sep;14(9):538-551. doi: 10.1038/s41574-018-0068-3.
  93. Pecce V, Sponziello M, Damante G, Rosignolo F, **Durante C**, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. *PLoS Genet*. 2018 Oct

15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678.

94. Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, **Durante C**, Filetti S, Fadda G. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. *Endocrine*. 2018 Nov;62(2):492-495. doi: 10.1007/s12020-018-1611-7.
95. Zatelli MC, Lamartina L, Meringolo D, Arvat E, Damiani L, Grani G, Nervo A, **Durante C**, Giacomelli L. Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient's characteristics, and risk factors. *J Endocrinol Invest*. 2018 Dec;41(12):1469-1475. doi: 10.1007/s40618-018-0946-5.
96. Rago T, Cantisani V, Ianni F, Chiovato L, Garberoglio R, **Durante C**, Frasoldati A, Spiezia S, Farina R, Vallone G, Pontecorvi A, Vitti P. Thyroid ultrasonography reporting: consensus of Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB) and Ultrasound Chapter of Italian Society of Medical Radiology (SIRM). *J Endocrinol Invest*. 2018 Dec;41(12):1435-1443. doi: 10.1007/s40618-018-0935-8.
97. Grani G, Lamartina L, Montesano T, Ronga G, Maggisano V, Falcone R, Ramundo V, Giacomelli L, **Durante C**, Russo D, Maranghi M. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. *J Endocrinol Invest*. 2019 Jan;42(1):85-90. doi: 10.1007/s40618-018-0889-x.
98. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, **Durante C**. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. *J Clin Endocrinol Metab*. 2019 Jan 1;104(1):95-102. doi: 10.1210/je.2018-01674.
99. Lamartina L, Montesano T, Falcone R, Biffoni M, Grani G, Maranghi M, Ciotti L, Giacomelli L, Ramundo V, Lo Monaco C, Di Gioia Cira R, Lucia P, Ronga G, **Durante C**. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT? *Endocr Pract*. 2019 Feb;25(2):165-169. doi: 10.4158/EP-2018-0393.
100. Celano M, Maggisano V, Lepore SM, Sponziello M, Pecce V, Verrienti A, **Durante C**, Maranghi M, Lucia P, Bulotta S, Damante G, Russo D. Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells. *Int J Endocrinol*. 2019 Feb 14;2019:5031696. doi: 10.1155/2019/5031696
101. Falcone R, Conte F, Fiscon G, Pecce V, Sponziello M, **Durante C**, Farina L, Filetti S, Paci P, Verrienti A. BRAF(V600E)-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. *Endocrine*. 2019 May;64(2):406-413. doi: 10.1007/s12020-019-01890-4.
102. Ramundo V, Lamartina L, Falcone R, Ciotti L, Lomonaco C, Biffoni M, Giacomelli L, Maranghi M, **Durante C**, Grani G. Is thyroid nodule location associated with malignancy risk? *Ultrasonography*. 2019 Jul;38(3):231-235. doi: 10.14366/usg.18050.
103. Cantisani V, David E, Grazhdani H, Rubini A, Radzina M, Dietrich CF, **Durante C**, Lamartina L, Grani G, Valeria A, Bosco D, Di Gioia C, Frattaroli FM, D'Andrea V, De Vito C, Fresilli D, D'Ambrosio F, Giacomelli L, Catalano C. Prospective Evaluation of Semiquantitative Strain Ratio and Quantitative 2D Ultrasound Shear Wave Elastography (SWE) in Association with TIRADS Classification for Thyroid Nodule Characterization. *Ultraschall Med*. 2019 Aug;40(4):495-503. doi: 10.1055/a-0853-1821.
104. Locati LD, Piovesan A, **Durante C**, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *Eur J Cancer*. 2019 Sep;118:35-40. doi:10.1016/j.ejca.2019.05.031.
105. Rullo E, Minelli G, Bosco D, Nardi F, Grani G, **Durante C**, Ascoli V. Indeterminate thyroid nodules (TIR3A/TIR3B) according to the new Italian Reporting System for Thyroid Cytology: a cytomorphological study. *Cytopathology*. 2019 Sep;30(5):475-484. doi: 10.1111/cyt.12732.
106. Bongiovanni M, Faquin W, Giovanella L, **Durante C**, Kopp P, Trimboli P. Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) on risk of malignancy in

- patients undergoing lobectomy/thyroidectomy for suspicious for malignancy or malignant fine-needle aspiration cytology findings: a systematic review and meta-analysis. *Eur J Endocrinol*. 2019 Oct;181(4):389-396. doi: 10.1530/EJE-19-0223.
107. Grani G, Ramundo V, Verrienti A, Sponziello M, **Durante C**. Thyroid hormone therapy in differentiated thyroid cancer. *Endocrine*. 2019 Oct;66(1):43-50. doi:10.1007/s12020-019-02051-3.
  108. Appetecchia M, Lauletta R, Barnabei A, Pieruzzi L, Terrenato I, Cavedon E, Mian C, Castagna MG, Elisei R; SIE (Italian Society of Endocrinology) Working Group. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. *Cancers (Basel)*. 2019 Oct 9;11(10). pii:E1516. doi: 10.3390/cancers11101516.
  109. Grani G, Ramundo V, Falcone R, Lamartina L, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Verrienti A, Schlumberger M, Filetti S, **Durante C**. Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound. *J Clin Endocrinol Metab*. 2019 Nov 1;104(11):4981-4989. doi:10.1210/jc.2019-00962.
  110. Trimboli P, Palermo A, Deandrea M, Piccardo A, Campenni A, Valabrega S, Grani G, Santolamazza G, Bottoni G, Barnabei A, Ramundo V, Lauletta R, Monte L, Ferrarazzo G, Paone G, Crosetto C, Ruggeri RM, Baldari S, Chiefari A, Vottari S, Giarnieri E, Perrella E, Limone P, **Durante C**, Giovanella L, Appetecchia M, Crescenzi A. Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study. *Endocrine*. 2019 Dec;66(3):557-562. doi: 10.1007/s12020-019-02013-9.
  111. Grani G, Tumino D, Ramundo V, Ciotti L, Lomonaco C, Armillotta M, Falcone R, Lucia P, Maranghi M, Filetti S, **Durante C**. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. *J Endocrinol Invest*. 2019 Dec;42(12):1485-1490. doi: 10.1007/s40618-019-01074-x.
  112. McLeod DSA, Zhang L, **Durante C**, Cooper DS. Contemporary debates in adult papillary thyroid cancer management. *Endocr Rev*. 2019 Dec 1;40(6):1481-1499. doi:10.1210/er.2019-00085.
  113. Filetti S, **Durante C**, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019 Dec 1;30(12):1856-1883. doi: 10.1093/annonc/mdz400.
  114. Mio C, Grani G, **Durante C**, Damante G. Molecular defects in thyroid dysgenesis. *Clin Genet*. 2020 Jan;97(1):222-231. doi: 10.1111/cge.13627.
  115. Lamartina L, Grani G, **Durante C**, Filetti S, Cooper DS. Screening for differentiated thyroid cancer in selected populations. *Lancet Diabetes Endocrinol*. 2020 Jan;8(1):81-88. doi: 10.1016/S2213-8587(19)30324-9.
  116. Tallini G, De Leo A, Repaci A, de Biase D, Bacchi Reggiani ML, Di Nanni D, Ambrosi F, Di Gioia C, Grani G, Rhoden KJ, Solaroli E, Monari F, Filetti S, **Durante C**. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. *Cancers (Basel)*. 2020 Jan 19;12(1):246. doi: 10.3390/cancers12010246.
  117. Grani G, Lamartina L, Ramundo V, Falcone R, Lomonaco C, Ciotti L, Barone M, Maranghi M, Cantisani V, Filetti S, **Durante C**. Taller-Than-Wide Shape: A New Definition Improves the Specificity of TIRADS Systems. *Eur Thyroid J*. 2020 Feb;9(2):85-91. doi: 10.1159/000504219.
  118. **Durante C**, Grani G. Clinically silent thyroid cancers: drop those needles and scalpels! *J Clin Endocrinol Metab*. 2020 Mar 1;105(3):dgz129. doi: 10.1210/clinem/dgz129.
  119. Castellana M, Piccardo A, Virili C, Scappaticcio L, Grani G, **Durante C**, Giovanella L, Trimboli P. Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma? *Cancer Cytopathol*. 2020 Apr;128(4):250-259. doi: 10.1002/cncy.22235.
  120. Falcone R, Sponziello M, Carletti R, Di Gioia C, Nardi F, Mio C, Pecce V, Abballe L, Grani G, Ramundo V, Damante G, **Durante C**, Filetti M, Roberto M, Marchetti P, Verrienti A. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. *Endocrine*. 2020 Apr;68(1):230-232. doi: 10.1007/s12020-020-02221-8.
  121. Verrienti A, Sponziello M, **Durante C**, Filetti S, Grani G. Comment on: BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. *Clin Endocrinol (Oxf)*. 2020 May;92(5):482-

483. doi: 10.1111/cen.14103.

122. Ramundo V, Sponziello M, Falcone R, Verrienti A, Filetti S, **Durante C**, Grani G. Low-risk papillary thyroid microcarcinoma: Optimal management toward a more conservative approach. *J Surg Oncol*. 2020 May;121(6):958-963. doi: 10.1002/jso.25848
123. Sponziello M, Brunelli C, Verrienti A, Grani G, Pecce V, Abballe L, Ramundo V, Damante G, Russo D, Lombardi CP, **Durante C**, Rossi ED, Straccia P, Fadda G, Filetti S. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules. *Endocrine*. 2020 May;68(2):458-465. doi: 10.1007/s12020-020-02271-y.
124. Barone M, Grani G, Ramundo V, Garritano T, **Durante C**, Falcone R. Fournier's gangrene during lenvatinib treatment: A case report. *Mol Clin Oncol*. 2020 Jun;12(6):588-591. doi: 10.3892/mco.2020.2031
125. Falcone R, Grani G, Ramundo V, Melcarne R, Giacomelli L, Filetti S, **Durante C**. Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies. *Front Oncol*. 2020 Jun 23;10:1128. doi: 10.3389/fonc.2020.01128.
126. Trimboli P, **Durante C**. Ultrasound risk stratification systems for thyroid nodule: between lights and shadows, we are moving towards a new era. *Endocrine*. 2020 Jul;69(1):1-4. doi: 10.1007/s12020-020-02196-6
127. Pecce V, Verrienti A, Abballe L, Carletti R, Grani G, Falcone R, Ramundo V, **Durante C**, Di Gioia C, Russo D, Filetti S, Sponziello M. Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid. *Cancers (Basel)*. 2020 Jul 14;12(7):E1892. doi: 10.3390/cancers12071892.
128. Ramundo V, Di Gioia CRT, Falcone R, Lamartina L, Biffoni M, Giacomelli L, Filetti S, **Durante C**, Grani G. Diagnostic Performance of Neck Ultrasonography in the Preoperative Evaluation for Extrathyroidal Extension of Suspicious Thyroid Nodules. *World J Surg*. 2020 Aug;44(8):2669-2674. doi: 10.1007/s00268-020-05482-6.
129. Grani G, Brenta G, Trimboli P, Falcone R, Ramundo V, Maranghi M, Lucia P, Filetti S, **Durante C**. Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults. *Cancers (Basel)*. 2020 Aug 30;12(9):2458. doi: 10.3390/cancers12092458
130. Grani G, Sponziello M, Pecce V, Ramundo V, **Durante C**. Contemporary thyroid nodule evaluation and management. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa322. doi: 10.1210/clinem/dgaa322.
131. Castellana M, Grani G, Radzina M, Guerra V, Giovanella L, Deandrea M, Ngu R, **Durante C**, Trimboli P. Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. *Eur J Endocrinol*. 2020 Sep;183(3):255-264. doi: 10.1530/EJE-20-0204.
132. Sodo A, Verri M, Palermo A, Naciu AM, Sponziello M, **Durante C**, Di Gioacchino M, Paolucci A, di Masi A, Longo F, Crucitti P, Taffon C, Ricci, MA, Crescenzi A. Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas. *Diagnostics* 2020 Dec 29;11(1):43. <https://doi.org/10.3390/diagnostics11010043>
133. Grani G, Zatelli MC, Alfò M, Montesano T, Torlontano M, Morelli S, Deandrea M, Antonelli A, Francese C, Ceresini G, Orlandi F, Maniglia CA, Bruno R, Monti S, Santaguida MG, Repaci A, Tallini G, Fugazzola L, Monzani F, Giubbini R, Rossetto R, Mian C, Crescenzi A, Tumino D, Pagano L, Pezzullo L, Lombardi CP, Arvat E, Petrone L, Castagna MG, Spiazzi G, Salvatore D, Meringolo D, Solaroli E, Monari F, Magri F, Triggiani V, Castello R, Piazza C, Rossi R, Ferraro Petrillo U, Filetti S, **Durante C**. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. *Thyroid*. 2021 Feb;31(2):264-271. doi: 10.1089/thy.2020.0272.
134. Giani C, Valerio L, Bongiovanni A, **Durante C**, Grani G, Ibrahim T, Mariotti S, Massa M, Pani F, Pellegriti G, Porcelli T, Salvatore D, Tavarrelli M, Torlontano M, Locati L, Molinaro E, Elisei R. Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. *Thyroid*. 2021 Feb;31(2):224-232. doi: 10.1089/thy.2020.0276.
135. Grani G, Lamartina L, Alfò M, Ramundo V, Falcone R, Giacomelli L, Biffoni M, Filetti S, **Durante C**. Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk. *J Clin Endocrinol Metab*. 2021 Mar 25;106(4):e1717-e1727. doi: 10.1210/clinem/dgaa973.

136. Grani G, Sponziello M, Filetti S, **Durante C**. Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we? *Curr Opin Otolaryngol Head Neck Surg*. 2021 Apr 1;29(2):107-112. doi: 10.1097/MOO.0000000000000698.
137. Trimboli P, Castellana M, Piccardo A, Romanelli F, Grani G, Giovanella L, **Durante C**. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. *Rev Endocr Metab Disord*. 2021 Jun;22(2):453-460. doi: 10.1007/s11154-020-09592-3.
138. Pecce V, Verrienti A, Fiscion G, Sponziello M, Conte F, Abballe L, **Durante C**, Farina L, Filetti S, Paci P. The role of FOSL1 in stem-like cell reprogramming processes. *Sci Rep*. 2021 Jul 19;11(1):14677. doi: 10.1038/s41598-021-94072-0.
139. Fresilli D, David E, Pacini P, Del Gaudio G, Dolcetti V, Lucarelli GT, Di Leo N, Bellini MI, D'Andrea V, Sorrenti S, Mascagni D, Biffoni M, **Durante C**, Grani G, De Vincentis G, Cantisani V. Thyroid Nodule Characterization: How to Assess the Malignancy Risk. Update of the Literature. *Diagnostics (Basel)*. 2021 Jul 30;11(8):1374. doi: 10.3390/diagnostics11081374.
140. Celletti I, Fresilli D, De Vito C, Bononi M, Cardaccio S, Cozzolino A, **Durante C**, Grani G, Grimaldi G, Isidori AM, Catalano C, Cantisani V. TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance? *Radiol Med*. 2021 Sep;126(9):1189-1200. doi: 10.1007/s11547-021-01349-5
141. Sibilio P, Bini S, Fiscion G, Sponziello M, Conte F, Pecce V, **Durante C**, Paci P, Falcone R, Norata GD, Farina L, Verrienti A. In silico drug repurposing in COVID-19: A network-based analysis. *Biomed Pharmacother*. 2021 Oct;142:111954. doi: 10.1016/j.biopha.2021.111954.
142. Grani G, Cera G, Conzo G, Del Gatto V, di Gioia CRT, Maranghi M, Lucia P, Cantisani V, Metere A, Melcarne R, Borcea MC, Scorziello C, Menditto R, Summa M, Biffoni M, **Durante C**, Giacomelli L. Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension? *J Clin Med*. 2021 Nov 13;10(22):5277. doi: 10.3390/jcm10225277.
143. Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, **Durante C**, Castagna MG. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). *Thyroid*. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248.
144. **Durante C**, Pecce V, Grani G. Management of cytologically indeterminate thyroid nodules: primum non nocere. *Pol Arch Intern Med*. 2021 Dec 22;131(12):16166. doi: 10.20452/pamw.16166.
145. Capriglione F, Verrienti A, Celano M, Maggisano V, Sponziello M, Pecce V, Gagliardi A, Giacomelli L, Aceti V, **Durante C**, Bulotta S, Russo D. Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer. *Endocrine*. 2022 Jan;75(1):185-193. doi: 10.1007/s12020-021-02847-2.
146. Prieditis P, Radzina M, Mikijanska M, Liepa M, Stepanovs K, Grani G, **Durante C**, Lamartina L, Trimboli P, Cantisani V. Non-Marked Hypoechoic Nodules: Multicenter Study on the Thyroid Malignancy Risk Stratification and Accuracy Based on TIRADS Systems Comparison. *Medicina (Kaunas)*. 2022 Feb 9;58(2):257. doi: 10.3390/medicina58020257.
147. Cantisani V, De Silvestri A, Scotti V, Fresilli D, Tarsitano MG, Polti G, Guiban O, Polito E, Pacini P, **Durante C**, Grani G, Isidori AM, Giannetta E, Sorrenti S, Trimboli P, Catalano C, Cirocchi R, Lauro A, D'Andrea V. US-Elastography With Different Techniques for Thyroid Nodule Characterization: Systematic Review and Meta-analysis. *Front Oncol*. 2022 Mar 16;12:845549. doi: 10.3389/fonc.2022.845549.
148. Maggisano V, Capriglione F, Verrienti A, Celano M, Gagliardi A, Bulotta S, Sponziello M, Mio C, Pecce V, **Durante C**, Damante G, Russo D. Identification of Exosomal microRNAs and Their Targets in Papillary Thyroid Cancer Cells. *Biomedicines*. 2022 Apr 21;10(5):961. doi: 10.3390/biomedicines10050961.
149. Pagano L, **Durante C**, Tufano RP. Editorial: Radiofrequency Ablation as an Alternative to Conventional Treatment. *Front Endocrinol (Lausanne)*. 2022 Apr 27;13:883809. doi: 10.3389/fendo.2022.883809



150. Hoang JK, Asadollahi S, **Durante C**, Hegedüs L, Papini E, Tessler FN. An International Survey on Utilization of Five Thyroid Nodule Risk Stratification Systems: A Needs Assessment with Future Implications. *Thyroid*. 2022 Jun;32(6):675-681. doi: 10.1089/thy.2021.0558.
151. Cozzolino A, Filardi T, Simonelli I, Grani G, Virili C, Stramazzo I, Santaguida MG, Locantore P, Maurici M, Gianfrilli D, Isidori AM, **Durante C**, Pozza C. Diagnostic accuracy of ultrasonographic features in detecting thyroid cancer in the transition age: a meta-analysis. *Eur Thyroid J*. 2022 Jun 14;11(3):e220039. doi: 10.1530/ETJ-22-0039
152. Pecce V, Sponziello M, Bini S, Grani G, **Durante C**, Verrienti A. Establishment and maintenance of thyroid organoids from human cancer cells. *STAR Protoc*. 2022 May 15;3(2):101393. doi: 10.1016/j.xpro.2022.101393
153. Filetti S, **Durante C**, Hartl DM, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol*. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009
154. Wirth LJ, **Durante C**, Topliss DJ, Winkquist E, Robenshtok E, Iwasaki H, Luster M, Elisei R, Leboulleux S, Tahara M. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. *Oncologist*. 2022 Jul 5;27(7):565-572. doi: 10.1093/oncolo/oyac065.
155. Sorrenti S, Dolcetti V, Radzina M, Bellini MI, Frezza F, Munir K, Grani G, **Durante C**, D'Andrea V, David E, Calò PG, Lori E, Cantisani V. Artificial Intelligence for Thyroid Nodule Characterization: Where Are We Standing? *Cancers (Basel)*. 2022 Jul 10;14(14):3357. doi: 10.3390/cancers14143357
156. Verrienti A, Grani G, Sponziello M, Pecce V, Damante G, **Durante C**, Russo D, Filetti S. Precision oncology for RET-related tumors. *Front Oncol*. 2022 Aug 24;12:992636. doi: 10.3389/fonc.2022.992636
157. Grani G, Filetti S, **Durante C**. New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows. *Ann Palliat Med*. 2022 Aug;11(8):2796-2801. doi: 10.21037/apm-22-603.
158. Trimboli P, Ferrarazzo G, Piccardo A, Lucchini B, **Durante C**. Operation rate and cancer prevalence among thyroid nodules with FNAC report of suspicious for malignancy (TIR4) or malignant (TIR5) according to Italian classification system: a systematic review and meta-analysis. *Endocrine*. 2022 Oct;78(1):24-31. doi: 10.1007/s12020-022-03165-x.
159. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Lucia P, Verrienti A, Filetti S, **Durante C**. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment. *Endocrine*. 2022 Nov;78(2):387-391. doi: 10.1007/s12020-022-03131-7
160. Grani G, Lamartina L, Montesano T, Giacomelli L, Biffoni M, Trulli F, Filetti S, **Durante C**. Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening. *Thyroid*. 2022 Nov;32(11):1392-1401. doi: 10.1089/thy.2022.0253.
161. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Verrienti A, Filetti S, **Durante C**. The legacy of the COVID-19 pandemics for thyroid cancer patients: towards the application of clinical practice recommendations. *Endocrine*. 2023 Jan;79(1):45-48. doi: 10.1007/s12020-022-03132-6.
162. Koot A, Soares P, Robenshtok E, Locati LD, de la Fouchardiere C, Luster M, Bongiovanni M, Hermens R, Ottevanger P, Geenen F, Bartès B, Rimmelé H, **Durante C**, Nieveen-van Dijkum E, Stalmeier P, Dedecjus M, Netea-Maier R. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma. *Eur J Cancer*. 2023 Jan;179:98-112. doi: 10.1016/j.ejca.2022.11.005.
163. Capezzone M, Tosti Balducci M, Morabito EM, **Durante C**, Piacentini P, Torregrossa L, Materazzi G, Giubbolini G, Mancini V, Rossi M, Alessandri M, Cartocci A. High Incidence of Thyroid Cancer in Southern Tuscany (Grosseto Province, Italy): Potential Role of Environmental Heavy Metal Pollution. *Biomedicines*. 2023 Jan 20;11(2):298. doi: 10.3390/biomedicines11020298.
164. Maggisano V, Capriglione F, Verrienti A, Celano M, Sponziello M, Pecce V, Russo D, **Durante C**,

- Bulotta S. Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cells. *Endocrine*. 2023 Mar;79(3):517-526. doi: 10.1007/s12020-022-03267-6.
165. Chou R, Dana T, Mayson SE, Cibas ES, **Durante C**, Solórzano CC, Mandel SJ, Orloff LA. Ultrasound Follow-Up of Benign Thyroid Nodules: A Scoping Review. *Thyroid*. 2023 Apr;33(4):420-427. doi: 10.1089/thy.2022.0692.
166. Scorziello C, **Durante C**, Biffoni M, Borcea MC, Consorti F, Laca A, Melcarne R, Ventrone L, Giacomelli L. The Size of a Thyroid Nodule with ACR TI-RADS Does Not Provide a Better Prediction of the Nature of the Nodule: A Single-Center Retrospective Real-Life Observational Study. *Healthcare (Basel)*. 2023 Jun 7;11(12):1673. doi: 10.3390/healthcare11121673
167. Grani G, Gentili M, Siciliano F, Albano D, Zilioli V, Morelli S, Puxeddu E, Zatelli MC, Gagliardi I, Piovesan A, Nervo A, Crocetti U, Massa M, Samà MT, Mele C, Deandrea M, Fugazzola L, Puligheddu B, Antonelli A, Rossetto R, D'Amore A, Ceresini G, Castello R, Solaroli E, Centanni M, Monti S, Magri F, Bruno R, Sparano C, Pezzullo L, Crescenzi A, Mian C, Tumino D, Repaci A, Castagna MG, Triggiani V, Porcelli T, Meringolo D, Locati L, Spiazzi G, Di Dalmazi G, Anagnostopoulos A, Leonardi S, Filetti S, **Durante C**. A data-driven approach to refine predictions of differentiated thyroid cancer outcomes: a prospective multicenter study. *J Clin Endocrinol Metab*. 2023 Jul 14;108(8):1921-1928. doi: 10.1210/clinem/dgad075.
168. Scorziello C, Borcea MC, Biffoni M, Pernazza A, Arienzo F, Melcarne R, Ventrone L, Laca A, Grani G, **Durante C**, Consorti F, Giacomelli L. Laterocervical lymph node metastases from suspected thyroidal primary site that turned out to be metastases of lung cancer: A case report. *Clin Case Rep*. 2023 Jul 21;11(7):e7417. doi: 10.1002/ccr3.7417.
169. Grani G, Del Gatto V, Cantisani V, Mandel SJ, **Durante C**. A reappraisal of suspicious sonographic features of thyroid nodules: shape is not an independent predictor of malignancy. *J Clin Endocrinol Metab*. 2023 Aug 18;108(9):e816-e822. doi: 10.1210/clinem/dgad092.
170. Trocchianesi S, Po A, Citarella A, Spinello Z, Rughetti A, Besharat ZM, Autilio TM, Pecce V, Verrienti A, Elisei R, **Durante C**, Catanzaro G, Ferretti E. Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH- Gli signaling pathway in acquired resistance. *Biomed Pharmacother*. 2023 Aug;164:114995. doi: 10.1016/j.biopha.2023.114995
171. **Durante C**, Hegedüs L, Czarniecka A, Paschke R, Russ G, Schmitt F, Soares P, Solymosi T, Papini E. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. *Eur Thyroid J*. 2023 Aug 14;12(5):e230067. doi: 10.1530/ETJ-23-0067. PMID: 37358008; PMCID: PMC10448590.
172. Capdevila J, Deandrea D, **Durante C**, Lebouleux S, Luster M, Netea-Maier R, Newbold K, Singer S, Sykiotis GP, Bartes B, Farnell K, Locati LD. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. *Eur Thyroid J*. 2023 Aug 8;12(5):e230068. doi: 10.1530/ETJ-23-0068.
173. Citarella A, Besharat ZM, Trocchianesi S, Autilio TM, Verrienti A, Catanzaro G, Splendiani E, Spinello Z, Cantara S, Zavattari P, Loi E, Romei C, Ciampi R, Pezzullo L, Castagna MG, Angeloni A, Elisei R, **Durante C**, Po A, Ferretti E. Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value. *Biomark Res*. 2023 Sep 19;11(1):82. doi: 10.1186/s40364-023-00522-4.
174. Pecce V, Sponziello M, Verrienti A, Grani G, Abballe L, Bini S, Annunziata S, Perotti G, Salvatori M, Zagaria L, Maggisano V, Russo D, Filetti S, **Durante C**. The role of miR-139-5p in radioiodine-resistant thyroid cancer. *J Endocrinol Invest*. 2023 Oct;46(10):2079-2093. doi: 10.1007/s40618-023-02059-7.
175. **Durante C**, Hegedüs L, Na DG, Papini E, Sapos JA, Baek JH, Frasoldati A, Grani G, Grant E, Horvath E, Hoang JK, Mandel SJ, Middleton WD, Ngu R, Orloff LA, Shin JH, Trimboli P, Yoon JH, Tessler FN. International Expert Consensus on US Lexicon for Thyroid Nodules. *Radiology*. 2023 Oct;309(1):e231481. doi: 10.1148/radiol.231481.
176. Pita JM, Raspé E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G, Libert F, Craciun L, Andry G, Wicquart L, Leteurtre E, Trésallet C, Marlow LA, Copland JA, **Durante C**, Maenhaut C, Cavaco BM, Dumont JE, Costante G, Roger PP. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. *Front Endocrinol (Lausanne)*. 2023 Oct 26;14:1247542. doi: 10.3389/fendo.2023.1247542.

177. Grani G, Lamartina L, Montesano T, Maranghi M, Filetti S, **Durante C**, Lopatriello S. Ultrasound screening for thyroid nodules and cancer in individuals with family history of thyroid cancer: a micro-costing approach. *J Endocrinol Invest*. 2023 Nov;46(11):2327-2330. doi: 10.1007/s40618-023-02087-3.
178. De Leo S, D'Elia S, Grani G, Dondi F, Bertagna F, Puxeddu E, Morelli S, Piovesan A, Nervo A, Zatelli MC, Gagliardi I, Samà MT, Aimaretti G, Crocetti U, Massa M, Deandrea M, Retta F, Pagano L, Rossi M, Solaroli E, Pezzullo L, Chiofalo MG, Pontecorvi A, Lombardi CP, Antonelli A, Patrizio A, Messuti I, Magri F, Spiazzi G, Ceresini G, Bruno R, Sparano C, Centanni M, Crescenzi A, Tallini G, Marotta V, Madeo B, Mian C, Filetti S, **Durante C**, Fugazzola L. A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis. *Thyroid*. 2023 Nov;33(11):1318-1326. doi: 10.1089/thy.2023.0052.
179. Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, Caruso FP, Panariello I, Gianni F, Carpino G, Gaudio E, Chiacchiarini M, Masuelli L, Sponziello M, Pecce V, Ramone T, Maino F, Dotta F, Ceccarelli M, Pezzullo L, **Durante C**, Castagna MG, Elisei R, Ferretti E. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. *J Endocrinol Invest*. 2023 Dec;46(12):2583-2599. doi: 10.1007/s40618-023-02115-2.
180. Biffoni M, Grani G, Melcarne R, Geronzi V, Consorti F, Ruggieri G, Galvano A, Razlighi MH, Iannuzzi E, Engel TD, Pace D, Di Gioia CRT, Boniardi M, **Durante C**, Giacomelli L. Drawing as a Way of Knowing: How a Mapping Model Assists Preoperative Evaluation of Patients with Thyroid Carcinoma. *J Clin Med*. 2024 Feb 28;13(5):1389. doi: 10.3390/jcm13051389.
181. Piticchio T, Russ G, Radzina M, Frasca F, **Durante C**, Trimboli P. Head-to-head comparison of American, European, and Asian TIRADSs in thyroid nodule assessment: systematic review and meta-analysis. *Eur Thyroid J*. 2024 Mar 15;13(2):e230242. doi: 10.1530/ETJ-23-0242.
182. Papini E, Guglielmi R, Novizio R, Pontecorvi A, **Durante C**. Management of low- risk papillary thyroid cancer. Minimally-invasive treatments dictate a further paradigm shift? *Endocrine*. 2024 May 20. doi: 10.1007/s12020-024-03864-7.

#### Articles in national journals

1. Filetti S, **Durante C**, Maranghi M. A genetic based disease management in inherited cancer syndromes: the multiple endocrine neoplasia model. *Supportive & Palliative Cancer Care*. 2006 Jan; 2 (suppl. 2): 13-16.
2. **Durante C**, Romagnoli E, Maranghi M, D'Aloiso L, Minisola S, D'Erasmus E, Filetti S. Hyperparathyroidism in multiple endocrine neoplasia type IIA. *Clinical Cases in Mineral and Bone Metabolism*. 2006 May- Aug; 3 (2): 162-6. [Indexed in Scopus]
3. Maranghi M, Coletta P, **Durante C**, Pergolini D, Filetti S. Cardiovascular disease and metabolic syndrome. *Recenti Prog Med*. 2006;97(12):719-26. [Indexed in PubMed, ISI Web of Science, Scopus]
4. **Durante C**, Cava F, Paciaroni A, Filetti S. Benign thyroid nodules: diagnostic and therapeutic approach. *Recenti Prog Med*. 2008;99(5):263-70. [Indexed in PubMed, ISI Web of Science, Scopus]

#### Books (edited and written)

1. David S Cooper, **Durante C**. Thyroid Cancer: A Case-Based Approach. Springer: ISBN: 978-3-319-22400-8 (Print) 978-3-319-22401-5 (Online)
2. Grani G, David S Cooper, **Durante C**. Thyroid Cancer: A Case-Based Approach. Second Edition. Springer: ISBN: 978-3-030-61918-3 (Print) 978-3-030-61919-0 (Online)

**Date** 31-05-2024

**Signature**

